OCEANBASE
19.10.2021 12:24:11 CEST | Business Wire | Press release
OceanBase, an enterprise-level distributed relational database provider, has drawn more than 21,300 users and 50 institutional partners to its open-source program within months of its official launch, with leading internet companies such as Trip.com, Kuaishou, Meituan and Bilibili joining the community.
Oceanbase, an Ant Group company, announced the latest updates on the new program at the Database Technology Conference China 2021 (DTCC2021), during which its partners shared their best practices for deploying or testing its open-source technologies.
OceanBase’s open-source community was officially launched on June 1, 2021, and since then, developers across the world that have joined the community have contributed more than 500 code commits and 600 original posts on technical practices.
Among the over 50 enterprises and organizations exploring further deployment of OceanBase, Nasdaq-listed one-stop travel service provider Trip.com is implementing the open-source version of OceanBase in its risk management and other business systems, and has also begun testing the enterprise version.
"Our database technologies are facing major challenges in several different areas, including handling the increasing number of database instances, managing multiple data centers, and deploying across multiple locations, while meeting requirements to reduce operation and maintenance costs and improve system uptime," said Chen Yao, a senior database expert at Trip.com. “OceanBase’s distributed architecture, combined with the team’s efficient technical support, is exactly what we need."
Yang Chuanhui, Chief Technology Officer of OceanBase, said, "Since the launch of our open-source program, OceanBase has been widely embraced by database developers, which further demonstrates that our commitment to an open-source strategy can support the standardization and adoption of distributed databases, accelerate the development of various products and technologies, and benefit more enterprises and developers."
OceanBase announced its comprehensive open-source program during the OceanBase 3.0 summit in June. Based on the Mulan Public License Version 2 and the Open-core model, OceanBase has open-sourced 3 million lines of its core codes.
OceanBase’s database technologies have been applied in all major Ant Group businesses. The enterprise version of OceanBase database also serves numerous institutions, including the Industrial and Commercial Bank of China, China Construction Bank, Bank of Nanjing, Sinopec, and China Mobile Zhejiang.
About OceanBase
Launched in 2010, OceanBase is an enterprise-level distributed relational database developed by Ant Group. OceanBase’s benefits over alternative solutions include strong data consistency, high availability, high performance, low cost, online scalability, and high compatibility with SQL standards and other mainstream relational databases. Its performance has been proven in Alipay's large-scale business scenarios and the annual 11.11 Global Shopping Festival. In May 2020, OceanBase set the world record for online transaction processing performance, with 707 million transactions per minute in a TPC-C benchmark test. OceanBase was officially registered as a separate company in June 2020.
To learn more, please visit: https://www.oceanbase.com/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005618/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom